Show simple item record

AuthorMusa, Omran A H
AuthorSyed, Asma
AuthorMohamed, Aisha M
AuthorChivese, Tawanda
AuthorClark, Justin
AuthorFuruya-Kanamori, Luis
AuthorXu, Chang
AuthorToft, Egon
AuthorBashir, Mohammed
AuthorAbou-Samra, Abdul Badi
AuthorThalib, Lukman
AuthorDoi, Suhail A
Available date2021-04-06T06:00:04Z
Publication Date2021-03-01
Publication NamePharmacological Research
Identifierhttp://dx.doi.org/10.1016/j.phrs.2021.105546
CitationMusa, Omran A H. et. al. "Metformin is comparable to insulin for pharmacotherapy in gestational diabetes mellitus: A network meta-analysis evaluating 6046 women"Pharmacological Research Volume 167, May 2021, 105546
Identifier105546
URIhttp://hdl.handle.net/10576/18092
AbstractThe comparative efficacy of gestational diabetes (GDM) treatments lack conclusive evidence for choice of first-line treatment. The aim of this study was to compare the efficacy of metformin and glibenclamide to insulin using a core outcome set (COS) to unify outcomes across trials investigating the treatment of gestational diabetes mellitus. A network meta-analysis (NMA) was conducted. PubMed, Embase, and Cochrane Controlled Register of Trials were searched from inception to January 2020. RCTs that enrolled pregnant women who were diagnosed with GDM and that compared the efficacy of different pharmacological interventions for the treatment of GDM were included. A generalized pairwise modelling framework was employed. A total of 38 RCTs with 6046 participants were included in the network meta-analysis. Compared to insulin, the estimated effect of metformin indicated improvements for weight gain (WMD -2·39kg; 95% CI -3·31 to -1·46), maternal hypoglycemia (OR 0·34; 95% CI 0·12 to 0·97) and LGA (OR 0·61; 95% CI 0·38 to 0·98). There were also improvements in estimated effects for neonatal hypoglycemia (OR 0·48; 95% CI 0·19 to 1·25), pregnancy induced hypertension (OR 0·63; 95% CI 0·37 to 1·06), and preeclampsia (OR 0·74; 95% CI 0·538 to 1·04), though with limited evidence against our model hypothesis of equivalence with insulin for these outcomes. Metformin is, at least, comparable to insulin for the treatment of GDM. Glibenclamide appears less favorable, in comparison to insulin, than metformin.
SponsorQNRF via NPRP10-0129-170274
Languageen
PublisherElsevier
SubjectGestational diabetes
core outcome set
glibenclamide
insulin
meta-analysis
metformin
network
pharmacotherapy
TitleMetformin is comparable to insulin for pharmacotherapy in gestational diabetes mellitus: A network meta-analysis evaluating 6046 women.
TypeArticle
Volume Number167
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record